Planned sale of 12,300 Enliven Therapeutics (NASDAQ: ELVN) shares

Rhea-AI Filing Summary

Enliven Therapeutics received a Form 144 notice from a holder planning to sell 12,300 shares of its common stock. The planned sale, through Jefferies LLC, has an indicated aggregate market value of $190,281.00, with an approximate sale date of 01/08/2026 on the Nasdaq exchange. The filing notes that 59,000,000 shares of common stock are outstanding.

The 12,300 shares to be sold were acquired on 01/25/2020 as founders shares from Enliven Therapeutics, with the same date shown as the date of payment and the nature of payment listed as “N/A.” The notice also includes the standard representation that the seller does not know of any undisclosed material adverse information about the issuer.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	12300	190281.00	59000000	01/08/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2020	Founders Shares	Enliven Therapeutics			12300	01/25/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Enliven Therapeutics (ELVN) Form 144 filing report?

The filing reports that a holder of Enliven Therapeutics common stock intends to sell 12,300 shares under Rule 144, using Jefferies LLC as broker, with an approximate sale date of 01/08/2026 on Nasdaq.

How many Enliven Therapeutics (ELVN) shares are planned to be sold and at what market value?

The notice covers a planned sale of 12,300 common shares of Enliven Therapeutics, with an indicated aggregate market value of $190,281.00 at the time referenced in the form.

How many Enliven Therapeutics (ELVN) shares are outstanding according to this Form 144?

The Form 144 states that there are 59,000,000 shares of Enliven Therapeutics common stock outstanding.

When and how were the Enliven Therapeutics (ELVN) shares being sold under Form 144 originally acquired?

The 12,300 shares to be sold were acquired on 01/25/2020 as founders shares from Enliven Therapeutics, with the form listing the nature of payment as “N/A”.

Which broker is handling the planned sale of Enliven Therapeutics (ELVN) shares in this Form 144?

The planned sale of Enliven Therapeutics common stock is to be handled by Jefferies LLC, located at 520 Madison Ave, 4th Floor, New York, NY 10022.

What representation does the seller make in this Enliven Therapeutics (ELVN) Form 144?

The seller represents that they do not know any material adverse information about the current or prospective operations of Enliven Therapeutics that has not been publicly disclosed.